PO-05-025 LONGER TERM OUTCOMES IN PATIENTS PRECLUDED FOR TRANSVENOUS PACEMAKER IMPLANTATION: EXPERIENCE WITH THE MICRA VR TRANSCATHETER PACEMAKER

The Micra leadless pacemaker is a safe and effective alternative to transvenous pacemakers (TVP). However, longer-term safety mortality in patients precluded for TVP not well characterized. To assess long-term among implanted with who are TVP. VR from the Post-Approval Registry (PAR) Acute Performance European Middle Eastern (MAP EMEA) registry were divided into groups based upon whether implanting physician considered patient be receiving pacing system. All-cause through 5-years post-implant was compared between single-chamber (SC-TVP) Medtronic product surveillance using univariate propensity weighted Cox models. Among 2,735 patients, 841 (30.7%) deemed SC-TVP implant primarily due history of CIED infection or venous access issues. Precluded younger (74.2 vs 76.6 years), more likely have prior (41.7% 7.6%), require dialysis (21.5% 3.0%), congestive heart failure (18.8% 11.5%). Five-year all-cause higher (HR: 1.93, 95% CI: 1.56 – 2.40, P<0.001); however, there no significant difference when comparing non-precluded 0.95, 0.77 1.16, P=0.59; Figure). Major complication rates at related system procedure 5.2% 4.1% (P=0.170). Pericardial effusion regardless severity 1.2% 0.7% (P=0.27). risk 5 years highest SC-TVP, despite major patients. similar Preclusion should outcomes